Get the Stockscreener App
1.8799
0.27%
0.0199
Telomir Pharmaceuticals Inc stock is traded at $1.8799, with a volume of 68,790.
It is up +0.27% in the last 24 hours and down -25.40% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$1.86
Open:
$1.97
24h Volume:
68,790
Relative Volume:
0.35
Market Cap:
$61.01M
Revenue:
-
Net Income/Loss:
$-13.08M
P/E Ratio:
-4.257
EPS:
-0.4416
Net Cash Flow:
-
1W Performance:
-5.33%
1M Performance:
-25.40%
6M Performance:
-60.06%
1Y Performance:
-66.58%
1-Day Range:
$1.82
$1.97
1-Week Range:
$1.82
$2.05
52-Week Range:
$1.82
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.865 | 61.01M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.75 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
514.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.50 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.26 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.01 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeriaan Ultra-Rare Genetic Disorder that Causes Rapid Aging - ACCESS Newswire
Revolutionary Progeria Treatment Shows First-Ever Cellular Aging Prevention in Children's Cells - Stock Titan
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria - Benzinga
TELO Rises on Promising Telomir-1 Preclinical Results - MSN
10 Best Growth Stocks Under $100 to Buy Now - Insider Monkey
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model - The Oklahoman
Telomir-1 shows promise in reversing Wilson’s disease symptoms By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports promising drug trial results By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports promising drug trial results - Investing.com
Telomir Pharmaceuticals Says Positive Preclinical Results For Telomir-1 In Wilson'S Disease Animal Model - marketscreener.com
Telomir-1 shows promise in reversing Wilson’s disease symptoms - Investing.com Australia
Breakthrough Wilson's Disease Treatment Reverses Brain, Liver, and Kidney Damage in Preclinical Study - Stock Titan
Nuveen Asset Management LLC Purchases New Shares in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome - Reno Gazette Journal
telomir pharmaceuticals reports promising preclinical results for telomir-1 By Investing.com - Investing.com South Africa
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder - AOL.com
Telomir Says Lead Candidate Telomir-1 Restored Gene Regulation in Animal Model of Werner Syndrome - marketscreener.com
telomir pharmaceuticals reports promising preclinical results for telomir-1 - Investing.com
Telomir Pharmaceuticals-New Data From Preclinical Study Of Its Lead Compound, Telomir-1, In Validated Animal Model Of Werner Syndrome - marketscreener.com
Revolutionary Anti-Aging Drug Resets Biological Clock, Reverses Multiple Aging Markers in Landmark Study - Stock Titan
Telomir Pharmaceuticals Joins BIO Convention for Partnerships - MSN
Telomir announces positive preclinical data for its novel oral AMD therapeutic - Ophthalmology Times
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - Cheboygan Daily Tribune
Telomir Pharmaceuticals To Present At BIO 2025, Eyes IND Filing For Telomir-1 - Nasdaq
Revolutionary Anti-Aging Drug Telomir-1 Heads to FDA Review: Multiple Disease Applications Revealed - Stock Titan
TELO stock touches 52-week low at $1.96 amid market challenges By Investing.com - Investing.com South Africa
Northern Trust Corp Has $625,000 Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
TELO stock touches 52-week low at $1.96 amid market challenges - Investing.com Nigeria
Telomir Pharmaceuticals reports breakthrough in AMD treatment - Investing.com Australia
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):